Biodesix (BDSX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Biodesix (BDSX) is set to release its Q2 2025 earnings on August 7th, with analysts predicting an earnings per share of ($0.07) and revenue of $18.47 million.
• The company has recently received multiple analyst downgrades, with price targets significantly reduced from $3.00 to as low as $1.50, although it maintains a consensus rating of "Moderate Buy."
• Biodesix shares have recently opened at $0.38 and have seen a 1-year price range between $0.17 and $2.04 amid reports of a negative net margin and return on equity.

Biodesix (NASDAQ:BDSX - Get Free Report) is expected to be releasing its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Biodesix to post earnings of ($0.07) per share and revenue of $18.47 million for the quarter. Biodesix has set its FY 2025 guidance at EPS.

Biodesix (NASDAQ:BDSX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $17.96 million during the quarter, compared to analysts' expectations of $19.50 million. Biodesix had a negative net margin of 54.28% and a negative return on equity of 167.28%. On average, analysts expect Biodesix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biodesix Price Performance

BDSX traded up $0.01 during midday trading on Friday, hitting $0.36. The company had a trading volume of 469,857 shares, compared to its average volume of 4,165,334. The company has a debt-to-equity ratio of 3.32, a quick ratio of 2.22 and a current ratio of 2.22. The company has a market capitalization of $53.23 million, a PE ratio of -1.25 and a beta of 0.97. Biodesix has a twelve month low of $0.17 and a twelve month high of $2.04. The firm's 50-day simple moving average is $0.31 and its 200-day simple moving average is $0.59.

Wall Street Analyst Weigh In

Several research firms have weighed in on BDSX. Craig Hallum lowered their price objective on shares of Biodesix from $3.00 to $1.50 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Scotiabank lowered their price objective on shares of Biodesix from $3.00 to $2.00 and set a "sector outperform" rating for the company in a research report on Wednesday, May 21st. William Blair restated a "market perform" rating on shares of Biodesix in a research report on Wednesday, May 14th. Lake Street Capital lowered their price objective on shares of Biodesix from $3.00 to $2.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Finally, Canaccord Genuity Group lowered their price target on shares of Biodesix from $2.50 to $1.50 and set a "buy" rating for the company in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $1.75.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.